Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$8.51 - $13.6 $1.56 Million - $2.49 Million
-182,800 Reduced 12.16%
1,320,290 $13.8 Million
Q2 2022

Aug 15, 2022

SELL
$7.31 - $11.85 $1.67 Million - $2.71 Million
-228,624 Reduced 13.2%
1,503,090 $14.6 Million
Q1 2022

May 16, 2022

BUY
$7.35 - $10.63 $3.28 Million - $4.75 Million
446,700 Added 34.76%
1,731,714 $14.2 Million
Q4 2021

Feb 14, 2022

BUY
$4.19 - $9.56 $1.04 Million - $2.37 Million
247,582 Added 23.86%
1,285,014 $12.3 Million
Q3 2021

Nov 15, 2021

BUY
$3.56 - $4.64 $1.1 Million - $1.43 Million
308,132 Added 42.25%
1,037,432 $4.81 Million
Q1 2021

May 17, 2021

BUY
$4.52 - $7.8 $451,999 - $780,000
100,000 Added 15.89%
729,300 $3.86 Million
Q4 2020

Feb 16, 2021

BUY
$4.37 - $9.46 $2.75 Million - $5.95 Million
629,300 New
629,300 $4.44 Million
Q3 2020

Nov 16, 2020

SELL
$8.56 - $26.93 $6.74 Million - $21.2 Million
-787,582 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$21.21 - $31.55 $39.8 Million - $59.3 Million
-1,878,433 Reduced 70.46%
787,582 $21.6 Million
Q1 2020

May 15, 2020

BUY
$18.43 - $38.04 $12.8 Million - $26.5 Million
696,110 Added 35.34%
2,666,015 $58.7 Million
Q2 2019

Aug 14, 2019

BUY
$31.16 - $39.46 $5.19 Million - $6.58 Million
166,667 Added 9.24%
1,969,905 $77.7 Million
Q1 2019

May 15, 2019

BUY
$19.96 - $38.62 $4.06 Million - $7.85 Million
203,238 Added 12.7%
1,803,238 $69.6 Million
Q2 2018

Aug 14, 2018

BUY
$26.0 - $29.9 $41.6 Million - $47.8 Million
1,600,000 New
1,600,000 $47.8 Million

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.